Integrated DNA Technologies has purchased next generation sequencing (NGS) research assays from Invitae Corporation under the trademarked name Archer.
The integration of IDT’s portfolio with the acquired NGS research assays—which have been foundational in researching novel cancer fusions—will empower labs with a solution to uncover biomarkers and advance cancer discoveries.
Demaris Mills, President of IDT, said: “The acquisition of the NGS research assays aligns with our focus to accelerate the pace of scientific discovery, laying the foundation for IDT to become a leading oncology research solutions provider. The products, tools, talent and licensed technology will enable us to grow our NGS platform and unlock new market opportunities for IDT.”
